Skip to content
sellWeak cluster of 510b5-1 plan

Peter Rahmer sold $90k of RLAY

See remarks at Relay Therapeutics, Inc.. 4,508 shares at an average of $20.03, traded Aug 26, 2026, filed Aug 28, 2026.

Warning score
19
Value
$90k
4,508 shares
Holdings after
223,657
-2% from before
From 52-week low
+450%
low $3.54, close $19.46
From 52-week high
-6%
high $20.75, as of Aug 26, 2026

Score components

  • Role
    Officer
    +15
  • Trade size
    $90k at market
    +9
  • Share of holdings sold
    Sold 2.0% of holdings
    0
  • Cluster
    5 insiders selling within 14 days
    +15
  • 10b5-1 plan
    Pre-scheduled under a 10b5-1 plan
    -20

What happened after comparable sells

Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.

Price around the trade, and since

From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.

RLAYOct 9, 2026 · close 17.88
Since filing Aug 28, 2026: -4.7%SPY +1.4% · excess -6.1%

Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™

Rows in this filing

Every transaction in Form 4 0001193125-26-374645, as filed. Open on EDGAR

DateTransactionSharesPriceValueHoldings afterFiled
Aug 26, 2026SOpen-market sale
Common Stock10b5-1
-4,508$20.03$90k223,657Aug 28, 2026

Related signals

Other insiders at Relay Therapeutics, Inc. and this insider’s other filings.

ScoreCompanyInsiderValueHoldingsFiled
30Weak
RLAYsell 210b5-1
Relay Therapeutics, Inc.
Thomas Catinazzo
Chief Financial Officer
$329k
17,717 shares
-14%
36Weak
RLAYsell 210b5-1
Relay Therapeutics, Inc.
Sanjiv Patel
President and CEO
$872k
48,199 shares
-9%
26Weak
RLAYsell 510b5-1
Relay Therapeutics, Inc.
Donald A Bergstrom
President, R&D
$162k
8,530 shares
-2%
37Weak
RLAYsell 510b5-1
Relay Therapeutics, Inc.
Thomas Catinazzo
Chief Financial Officer
$336k
17,717 shares
-13%
44Moderate
RLAYsell 510b5-1
Relay Therapeutics, Inc.
Sanjiv Patel
President and CEO
$913k
48,199 shares
-8%
57Moderate
RLAYsell 5
Relay Therapeutics, Inc.
SVF Pauling (Cayman) Ltd
owner
$116M
6,000,000 shares
-22%
37Weak
RLAYsell 410b5-1
Relay Therapeutics, Inc.
Thomas Catinazzo
Chief Financial Officer
$350k
17,717 shares
-11%
45Moderate
RLAYsell 410b5-1
Relay Therapeutics, Inc.
Sanjiv Patel
President and CEO
$980k
48,199 shares
-8%
41Moderate
RLAYsell 3
Relay Therapeutics, Inc.
Donald A Bergstrom
President, R&D
$42k
2,237 shares
-1%
42Moderate
RLAYsell 3
Relay Therapeutics, Inc.
Thomas Catinazzo
Chief Financial Officer
$27k
1,459 shares
-1%

Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.

Peter Rahmer sold $90k of RLAY | InsiderTell